Scalpa Recalls Scalpa Numb Maximum Strength Topical Anesthetic Cream Due to Failure to Meet Child Resistant Packaging Requirement; Risk of Poisoning (Recall Alert)

What was recalled

The U.S. Consumer Product Safety Commission (CPSC) has issued a recall alert concerning a specific topical anesthetic product manufactured and distributed by the brand Scalpa. This action, announced on January 14, 2021, targets the "Scalpa Numb Maximum Strength Topical Anesthetic Cream." It is important to note that this recall does not involve every product made by Scalpa, but rather focuses exclusively on this particular formulation and packaging configuration. The company has initiated a direct notification process for all known purchasers, urging them to verify whether their specific items fall under this safety notice.

To help you determine if your product is part of this recall, it is crucial to identify the exact physical characteristics of the recalled item. The affected product comes in a 10-gram tube that features a distinct black and white color scheme. The tube is capped with a white lid, which is a standard design element but not unique enough on its own to confirm the recall status without further inspection. The labeling on the exterior of the tube clearly displays the brand name "SCALPANUMB" alongside the description "Maximum Strength Topical Anesthetic Cream." These printed details are primary indicators, but they must be cross-referenced with other specific markings to ensure accuracy.

Beyond the general description, several unique identifiers on both the tube and its packaging box can confirm whether a unit is included in this recall. On the outside of the retail box, you should look for the Universal Product Code (UPC), which is listed as 857076008689. Additionally, the box may display specific batch information; the recalled units are associated with Batch Number 1000000101 and Code: C1. Inside the tube, near the crimped end where the product is sealed, the expiration date is marked as EXP 202307. If your product matches these physical descriptions and codes, it is part of the recalled lot. Consumers are advised to check these details carefully against any packaging they may still have on hand. While the recall does not specify the total number of units sold or the specific retail locations where they were distributed, the scope is defined by these precise manufacturing and labeling details.

The reason for this targeted recall lies in regulatory compliance rather than product efficacy or ingredient safety per se. The issue is not with the lidocaine content itself, but with how it was packaged. Under the Poison Prevention Packaging Act (PPPA), certain hazardous substances must be sold in child-resistant packaging to prevent accidental ingestion by young children. The Scalpa Numb Maximum Strength Topical Anesthetic Cream, as distributed in this batch, failed to meet these mandatory child-resistant packaging requirements. This regulatory gap is what prompted the CPSC and Scalpa to issue this alert, ensuring that consumers can remove the product from their homes until a safer alternative or remedy is provided.

The hazard, explained

To understand why this recall is necessary, it helps to look past the product’s label and examine the specific physical failure that triggered the CPSC’s action. The core issue here is not with the cream itself—Scalpa Numb Maximum Strength Topical Anesthetic Cream is designed to work as intended—but rather with the container holding it. Under federal law, specifically the Poison Prevention Packaging Act (PPPA), certain substances that can be harmful if swallowed must be sold in packaging that is difficult for young children to open within a reasonable time. Lidocaine, the active ingredient in this product, falls into this category of regulated substances because it poses a significant risk of poisoning to young children if ingested.

The failure identified in this recall is that the packaging used for Scalpa Numb does not meet these stringent child-resistant standards. While the cap may appear secure to an adult hand, it lacks the complex mechanism required to deter curious toddlers or preschoolers. Young children often develop fine motor skills and problem-solving abilities faster than safety regulations anticipate. A standard screw-top or snap-on lid that is easy for an adult to manipulate can be opened by a determined child in seconds. Because the packaging is not child-resistant, there is no physical barrier preventing a young child from accessing the contents of the tube.

The danger arises from the combination of accessibility and the potency of the medication. Lidocaine is a local anesthetic that works by blocking nerve signals in the body. While safe for adults when used as directed on intact skin, it becomes highly toxic if swallowed. When ingested, lidocaine is absorbed into the bloodstream much more rapidly than it would be through the skin. This can lead to systemic poisoning, which affects the central nervous system and the cardiovascular system. In young children, whose bodies are smaller and metabolize drugs differently than adults, even a small amount of this cream can result in severe health consequences.

Poisoning from ingested topical anesthetics can manifest as drowsiness, confusion, seizures, irregular heartbeat, or difficulty breathing. These symptoms can escalate quickly, turning a moment of curiosity into a medical emergency. The CPSC’s concern is rooted in the high probability of accidental ingestion given the product's form factor. Creams and gels are often attractive to children due to their texture and scent, and when placed in non-compliant packaging, they become an easy target for exploration. This recall addresses that specific vulnerability by ensuring that consumers remove the hazard from their homes before it can lead to an incident.

It is also important to note that while no incidents have been reported to date, the risk is inherent in the design flaw. The absence of reported cases does not mean the risk is low; it simply means that, so far, no one has been harmed. However, the potential for harm is real and preventable. By acknowledging that the packaging fails to meet the PPPA requirements, Scalpa and the CPSC are prioritizing prevention over reaction. The goal is to stop any potential poisoning before it starts, ensuring that a product intended for pain relief does not inadvertently become a source of acute medical distress for a child.

Who is most at risk

When we look at this specific recall, the primary group at immediate and severe risk consists of young children, particularly those under the age of five. The core issue here is not that the product itself is inherently dangerous when used as intended, but rather that it lacks the mandatory child-resistant packaging required by federal law for products containing significant amounts of lidocaine. Lidocaine is a powerful local anesthetic, and while it is effective for numbing pain, it can be toxic if absorbed through the skin in large quantities or if ingested accidentally. Young children are uniquely vulnerable to this type of hazard because their bodies are smaller, meaning that even a small amount of the cream can result in a dangerous concentration in their bloodstream. Furthermore, young children explore the world by putting things in their mouths and do not understand the concept of "medicine" or "pain relief." They may mistake the tube for a treat or a toy, especially if it is left within reach on a counter, nightstand, or shelf.

The risk extends beyond just the immediate user to anyone who shares living space with young children. This includes parents, guardians, caregivers, and older siblings who might leave the product accessible after use. The recall notes that the packaging is a standard black and white tube with a simple white cap. For adults, this cap is easy to open and close, which is convenient for daily use. However, for a toddler or a curious preschooler, this type of closure offers virtually no barrier. These closures are not designed to withstand the persistence and dexterity of a child under five years old. Therefore, any household that stores this cream in a place where a child can access it—whether it is a bathroom cabinet without a lock, a bedroom dresser, or a travel bag—is creating an environment where an accidental poisoning could occur.

While the primary concern is young children, we must also consider individuals who might be using the product for legitimate medical reasons but are at risk of accidental exposure due to confusion or forgetfulness. For example, older adults or individuals with cognitive impairments who use topical anesthetics for joint pain or skin conditions may accidentally apply more than the recommended dose, leading to systemic absorption issues. Additionally, if a caregiver is assisting someone with this cream and then leaves it unattended, that same individual becomes part of the chain of custody that could lead to a child finding it. It is important to remember that while no incidents have been reported yet, the potential for harm is real because the barrier between the user and the hazard—the packaging—has failed to meet safety standards. The vulnerability lies in the gap between the product's convenience and its lack of protective design for homes with curious little ones.

Ultimately, the people most at risk are those who own this specific item and keep it in an accessible location. This is not a scare tactic; it is a factual assessment of how chemical exposure works in households. If you have young children in your home, they are the primary demographic to worry about because they cannot judge dosage or recognize danger signs. They rely entirely on the safety features built into the product and the vigilance of adults around them. Since the packaging does not provide that extra layer of protection, the responsibility shifts entirely to storage habits. If you have this cream in your home, assume that a child could get to it unless it is locked away or stored high up where they cannot reach it, even if you do not currently see any signs of tampering. The risk is latent, waiting for an opportunity, which makes proactive prevention the only reliable safeguard.

How to tell if you have the recalled item

If you are unsure whether the tube of topical anesthetic sitting in your medicine cabinet or on a shelf at home is part of this specific recall, do not guess. The safety risk hinges entirely on precise identification because the packaging does not visually scream "danger" to the untrained eye. You need to physically inspect the product to confirm it matches the exact specifications outlined by the Consumer Product Safety Commission (CPSC) and Scalpa. This is not a broad category recall; it targets a very specific configuration of the Scalpa Numb Maximum Strength Topical Anesthetic Cream.

Start by looking at the tube itself. The recalled item is exclusively the 10-gram version of the cream. It comes in a distinctive black and white tube, which might be easy to overlook if it is tucked away in a drawer. Crucially, look at the cap. The product in question has a white cap. If your tube has a different colored cap or is a different size, such as a 20-gram or 50-gram variant, it is not part of this specific recall notice, though you should always check the label for other potential issues.

Next, examine the text printed on the side of the tube. You are looking for very specific labeling details. The brand name "SCALPANUMB" must be clearly visible, along with the description "Maximum Strength Topical Anesthetic Cream." These words are not just marketing; they are the primary identifiers that distinguish this product from other numbing creams or lidocaine products on the market. If the text is faded or missing, it may be a different batch or an older version, but you should treat any uncertainty with caution.

The most reliable way to confirm if your item is affected is to check the expiration date and the manufacturing codes. Look at the crimped end of the tube where the metal is sealed shut. You need to find the expiration date marked as "EXP 202307." This specific date code is a key filter for this recall. If the expiration date is different, your product is likely not part of this batch. Additionally, check the outer box if you still have it. The box should display the batch number "1000000101," the code "C1," and the Universal Product Code (UPC) "857076008689." These numbers are printed on the outside of the packaging and serve as the definitive proof that your item was part of the distribution run that failed to meet child-resistant packaging standards. If you cannot find these specific codes, or if the expiration date does not match, it is highly probable that your product is safe from this particular recall issue.

• Product Name: Scalpa Numb Maximum Strength Topical Anesthetic Cream
• Size: 10 grams
• Tube Appearance: Black and white tube with a white cap
• Label Text: "SCALPANUMB" and "Maximum Strength Topical Anesthetic Cream"
• Expiration Date: EXP 202307 (located on the crimped end of the tube)
• Batch Code: 1000000101
• Code: C1
• UPC: 857076008689 (on the box)

What to do — step by step

Your refund, repair, or replacement options

If you have identified the recalled Scalpa Numb Maximum Strength Topical Anesthetic Cream in your home, the most important thing to understand is that this specific product cannot be repaired, fixed, or upgraded. Because the issue stems from the packaging failing to meet federal child-resistant safety standards—a fundamental design and regulatory compliance flaw rather than a defect in the cream itself—the manufacturer has determined that no technical correction can make the existing units safe for use around children. Therefore, your only available remedy is a full financial refund or store credit. This distinction is crucial because you might be tempted to try to simply replace the cap or find a third-party child-resistant container to keep the product. Please do not attempt this. The recall is issued because the packaging itself does not meet the rigorous testing requirements of the Poison Prevention Packaging Act (PPPA). Using a non-compliant container, even if modified, does not resolve the legal and safety violation, nor does it guarantee that a makeshift solution will prevent a determined toddler from accessing the lidocaine.

The good news is that Scalpa has taken the initiative to directly notify all known purchasers of this recall. This means you likely already have information in your possession regarding how to proceed. However, if you do not receive direct communication or wish to take immediate action yourself, the process is straightforward and designed to be hassle-free. You are entitled to a full refund of the purchase price. There are no restocking fees, no requirements to return the physical product (though you may choose to dispose of it safely), and no complicated forms to fill out online for basic compensation. The company has set up dedicated channels specifically to handle these inquiries efficiently, recognizing that this is a safety-sensitive situation rather than a standard customer service complaint.

To initiate your refund or store credit, you have three convenient options. You can call the dedicated toll-free number at 855-424-7828. This line is staffed by representatives who are prepared to assist you with the recall process specifically. Please note that these calls can be answered from 9 a.m. to 5 p.m. Mountain Time, Monday through Friday. If you prefer written communication or need to provide order details such as your receipt number, you can email care@scalpashop.com. Alternatively, for those who prefer digital self-service, Scalpa has created a specific landing page on their website. Simply visit www.scalpashop.com and navigate to the “Recall - Important Safety Information - Scalpa Numb” section. This page consolidates all necessary instructions and links to ensure you get the correct information without searching through general support pages.

When contacting Scalpa, it helps to have your product details ready, though they may not be strictly required for a refund. Having the batch number (1000000101), the code (C1), and the UPC (857076008689) on hand can expedite verification if needed. More importantly, have your proof of purchase ready. Once you connect with a representative or submit your request online, clearly state that you are participating in the January 14, 2021, recall for Scalpa Numb Maximum Strength Topical Anesthetic Cream due to child-resistant packaging failure. Be clear about whether you prefer a refund to your original payment method or store credit. Store credit is often processed faster as it remains within their ecosystem, but a full cash refund is your right if you prefer not to purchase from them again. Do not hesitate to ask questions during this process; the company has explicitly stated they are handling these notifications and remedies with priority due to the potential poisoning hazard involved.

What can happen if you ignore it

When a product recall involves a failure to meet child-resistant packaging standards, the primary concern is not necessarily that the cream itself is dangerous when used exactly as intended by an adult. Instead, the danger lies in accessibility. By ignoring this recall and keeping the Scalpa Numb Maximum Strength Topical Anesthetic Cream in its current, non-compliant tube, you are leaving a potent medical substance within easy reach of young children who lack the cognitive ability to understand what they are holding or the physical dexterity to open proper safety caps. The consequence of ignoring this warning is that a child could ingest or absorb a significant amount of lidocaine, leading to serious poisoning.

Lidocaine is a local anesthetic, which means it works by blocking nerve signals in the body. While this is helpful for numbing pain in adults, it can have profound and dangerous effects on a developing child’s nervous system. If a child manages to squeeze out even a small amount of this cream and swallows it, or if they rub it into their eyes or open wounds, the drug enters their system rapidly. Because children have smaller bodies and different metabolic rates than adults, the same dose that might be harmless for an adult can cause severe toxicity in a toddler. The symptoms of lidocaine poisoning can escalate quickly and include drowsiness, confusion, vomiting, difficulty breathing, seizures, and irregular heart rhythms. In severe cases, without immediate medical intervention, this can be life-threatening.

It is important to note that while the CPSC recall alert currently lists no reported incidents or injuries, the absence of reported cases does not mean the risk is zero. Many potential poisonings go unreported because parents may not immediately recognize the symptoms as drug-related, or they may seek emergency care without mentioning the specific product involved. Waiting for a tragedy to occur before acting is a gamble you do not need to take. The packaging flaw—specifically the lack of child-resistant features—creates a static hazard that remains present every time the tube is opened or left on a counter. Ignoring the recall means accepting that any family member, pet, or curious visitor could potentially access this substance at any moment.

Furthermore, using a recalled product can complicate matters if an accident does occur. If you continue to use the cream and a poisoning incident happens, it may be more difficult to trace the source of the exposure or process insurance claims, as the product was known to be non-compliant with federal safety laws. The simplest path to safety is to remove the variable entirely. By stopping use immediately and storing the item securely while you arrange for a refund, you eliminate the possibility of accidental exposure. Do not wait until you have an emergency to realize that the packaging should have been different. Act now to ensure that this product never becomes a source of fear or medical crisis in your home.

Staying safe: broader tips

When dealing with topical anesthetics like lidocaine creams, the primary danger often lies not in the product itself, but in how easily it can be mistaken for something harmless. Because these creams are frequently used for minor skin irritations, insect bites, or sunburns, they often end up in bathrooms and medicine cabinets alongside children’s toys or snacks. To prevent accidental ingestion, treat every topical medication with the same respect you would give to prescription drugs. Store them in high, locked cabinets whenever possible. If a lock is not available, choose a location that is completely out of your child’s line of sight and reach. Remember that young children are curious explorers; they do not understand labels or warnings, so physical barriers are far more effective than verbal instructions.

It is also crucial to understand the difference between "child-resistant" packaging and "safety caps." Many consumers assume that any cap that requires twisting or pressing down is safe for children. However, only packaging that meets specific standards set by the Consumer Product Safety Commission (CPSC) under the Poison Prevention Packaging Act (PPPA) is truly child-resistant. These caps require a combination of strength and dexterity that most children under five cannot yet master. Never rely on the cap alone if you have young children in your home. Always double-check that the container has been resealed properly after every use, as even partially opened packages can be accessed by persistent toddlers who have learned to manipulate simple closures.

Beyond storage, maintaining a habit of checking for product recalls is one of the most effective ways to protect your family’s health. The CPSC maintains a database of recalls that ranges from toys with choking hazards to electronics with fire risks. Set aside time once or twice a year to review the products you have at home, especially those involving chemicals, batteries, or mechanical parts. You can sign up for email alerts from the CPSC to receive notifications directly when new recalls are issued for products you own or have purchased in the past. This proactive approach ensures that you are aware of potential dangers before they result in harm.

Finally, educate all caregivers, including babysitters and relatives, about the specific risks associated with over-the-counter medications. Ensure they know where these items are stored and emphasize that "natural" or "over-the-counter" does not mean "safe for everyone." By combining secure storage, an understanding of safety standards, and active monitoring of official recall information, you create a robust layer of protection around your family. Safety is not just about reacting to problems; it is about building habits that prevent them from happening in the first place.